eviti Medical Advisory Board Welcomes New Member Reshma Jagsi, M.D., Ph.D. Radiation Oncology Researcher
Philadelphia, PA – eviti, Inc., an independent health information technology and oncology decision-support company, recently announced that Dr. Reshma Jagsi, Associate Professor of Radiation Oncology at the University of Michigan has joined 14 other expert oncology specialists on the Medical Advisory Board.
Dr. Jagsi is nationally recognized for her research in advancing radiation treatments of breast cancer and for improving quality of care through the understanding of patient decision-making, cost and access to appropriate care. Dr. Jagsi is the recipient of funding from the National Institutes of Health and the American Cancer Society and previously also from the Robert Wood Johnson Foundation.
“With her extensive research, including works published in journals such as the New England Journal of Medicine, JAMA, the Journal of the National Cancer Institute, and the Journal of Clinical Oncology, Dr. Jagsi brings outstanding expertise to the eviti Board relating to breast cancer and advancing quality and cost-effective use of radiation technology,” said Dr. Arlene Forastiere, SVP, Medical Affairs and Medical Advisory Board Chairwoman at eviti, Inc.
Dr. Jagsi received her undergraduate and medical degrees from Harvard University and obtained a doctorate in Social Policy from Oxford University. She completed her residency training in Radiation Oncology at the Massachusetts General Hospital/Harvard Radiation Oncology Program and completed a fellowship at the Harvard Center for Ethics.
About eviti, Inc.
eviti, Inc. is a leading health information technology and clinical decision-support company delivering solutions to improve the quality of cancer care and reduce its cost. eviti represents the culmination of almost a decade of experience providing oncology treatment intelligence, uniquely delivering value to all parties in the care process by ensuring quality care is prescribed from the start.
eviti’s growing national prominence is evidenced by the 2,000+ oncology practices already registered to use the eviti platform. eviti’s independent, non-proprietary digital oncology treatment library is one of the most comprehensive and current of its kind, meticulously compiled from the world’s leading sources. eviti’s treatment knowledge base and patent-pending decision-support engine help oncologists select a treatment option that is both evidence-based and compliant with each patient’s insurance plan language at the moment of prescribing. This transparent approach streamlines workflow and reimbursement, reduces variability in clinical care, and results in cost efficiencies. eviti allows the best cancer care to be available everywhere. For more information, visit www.eviti.com.